Literature DB >> 11819335

Interaction between cisplatin, 5-fluorouracil and vincristine on human hepatoma cell line (7721).

Wei-Xue Tang, Ping-Yan Cheng, Yun-Peng Luo, Rui-Xue Wang.   

Abstract

AIM:To evaluate the killing effects of CDDP, 5-Fu and VCR on human hepaoma cell line (7721).
METHODS: The median-effect principle was used.
RESULTS: Killing effects of the individual drug were enhanced as the median concentration increased. Antagonism was produced when two drugs were used at a higher concentration (CI > 1), and synergism was achiened when CI < 1. Finally, the effect was influenced by both the ratios of drug concentration and the sequence of administration.
CONCLUSION: The drug administration order and drug concentrations are significant factors that need to be considered in clinical practice.

Entities:  

Year:  1998        PMID: 11819335      PMCID: PMC4767741          DOI: 10.3748/wjg.v4.i5.418

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

1.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

2.  Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines.

Authors:  B K Chang; R Gutman; T C Chou
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

3.  Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; H C Ottenheijm; W J de Grip
Journal:  Anticancer Drugs       Date:  1994-02       Impact factor: 2.248

4.  Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.

Authors:  S B Howell; D Hom; R Sanga; J S Vick; I S Abramson
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

5.  Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.

Authors:  T T Chang; S C Gulati; T C Chou; R Vega; L Gandola; S M Ibrahim; J Yopp; M Colvin; B D Clarkson
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

6.  Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.

Authors:  T T Chang; S Gulati; T C Chou; M Colvin; B Clarkson
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

7.  Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.

Authors:  K S Smith; B A Folz; E G Adams; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.

Authors:  J T Lee; S Park; J H Lee; B K Kim; N K Kim
Journal:  J Korean Med Sci       Date:  1996-02       Impact factor: 2.153

9.  Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.

Authors:  N Kohno; T Ohnuma; M Kaneko; J F Holland
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

  9 in total
  2 in total

1.  Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.

Authors:  Jordan S Taylor; Burcin Yavuz; Jasmine Zeki; Lauren Wood; Naohiko Ikegaki; Jeannine Coburn; Kristin Harrington; Hiroyuki Shimada; David L Kaplan; Bill Chiu
Journal:  Surgery       Date:  2020-02-28       Impact factor: 3.982

2.  Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats.

Authors:  Yin-Cheng He; Ji-Wei Chen; Jun Cao; Ding-Yu Pan; Jian-Guo Qiao
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.